Apolipoprotein C-II: the re-emergence of a forgotten factor.
Journal
Current opinion in lipidology
ISSN: 1473-6535
Titre abrégé: Curr Opin Lipidol
Pays: England
ID NLM: 9010000
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
pubmed:
26
4
2020
medline:
17
6
2021
entrez:
26
4
2020
Statut:
ppublish
Résumé
Apolipoprotein C-II (apoC-II) is a critical cofactor for the activation of lipoprotein lipase (LPL), a plasma enzyme that hydrolyzes triglycerides (TG) on TG-rich lipoproteins (TRL). Although apoC-II was first discovered nearly 50 years ago, there is renewed interest in it because of the recent efforts to develop new drugs for the treatment of hypertriglyceridemia (HTG). The main topic of this review will be the development of apoC-II mimetic peptides as a possible new therapy for cardiovascular disease. We first describe the biochemistry of apoC-II and its role in TRL metabolism. We then review the clinical findings of HTG, particularly those related to apoC-II deficiency, and how TG metabolism relates to the development of atherosclerosis. We next summarize the current efforts to develop new drugs for HTG. Finally, we describe recent efforts to make small synthetic apoC-II mimetic peptides for activation of LPL and how these peptides unexpectedly have other mechanisms of action mostly related to the antagonism of the TG-raising effects of apoC-III. The role of apoC-II in TG metabolism is reviewed, as well as recent efforts to develop apoC-II mimetic peptides into a novel therapy for HTG.
Identifiants
pubmed: 32332429
doi: 10.1097/MOL.0000000000000680
pii: 00041433-202006000-00007
doi:
Substances chimiques
Apolipoprotein C-II
0
Apolipoprotein C-III
0
Lipoproteins
0
Lipoproteins, HDL
0
Peptides
0
Triglycerides
0
apolipoprotein C-II (St Michael)
0
lipoprotein triglyceride
0
Lipoprotein Lipase
EC 3.1.1.34
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
147-153Références
Nordestgaard BG. TG-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res 2016; 118:547–563.
Toth PP. TG-rich lipoproteins as a causal factor for cardiovascular disease. Vasc Health Risk Manag 2016; 12:171–183.
Olivecrona G. Role of lipoprotein lipase in lipid metabolism. Curr Opin Lipidol 2016; 27:233–241.
Wolska A, Dunbar RL, Freeman LA, et al. Apolipoprotein C-II: new findings related to genetics, biochemistry, and role in TG metabolism. Atherosclerosis 2017; 267:49–60.
Brown WV, Levy RI, Fredrickson DS. Further characterization of apolipoproteins from the human plasma very low density lipoproteins. J Biol Chem 1970; 245:6588–6594.
Korn ED. Clearing factor, a heparin-activated lipoprotein lipase. II. Substrate specificity and activation of coconut oil. J Biol Chem 1955; 215:15–26.
Amar MJA, Sakurai T, Sakurai-Ikuta A, et al. A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum TGs in apolipoprotein E-knockout mice. J Pharmacol Exp Ther 2015; 352:227–235.
Sakurai T, Sakurai A, Vaisman BL, et al. Creation of apolipoprotein C-II (ApoC-II) mutant mice and correction of their hypertriglyceridemia with an ApoC-II mimetic peptide. J Pharmacol Exp Ther 2016; 356:341–353.
Komatsu T, Sakurai T, Wolska A, et al. Apolipoprotein C-II mimetic peptide promotes the plasma clearance of TG-rich lipid emulsion and the incorporation of fatty acids into peripheral tissues of mice. J Nutr Metab 2019; 2019:7078241.
Liu C, Gates KP, Fang L, et al. Apoc2 loss-of-function zebrafish mutant as a genetic model of hyperlipidemia. Dis Model Mech 2015; 8:989–998.
Wolska A, Lo L, Sviridov DO, et al. A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma TGs. Sci Transl Med 2020; 12:pii: eaaw7905.
Reimund M, Wolska A, Risti R, et al. Apolipoprotein C-II mimetic peptide is an efficient activator of lipoprotein lipase in human plasma as studied by a calorimetric approach. Biochem Biophys Res Commun 2019; 519:67–72.
Hortin GL, Sviridov D, Anderson NL. High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. Clin Chem 2008; 54:1608–1616.
Kei AA, Filippatos TD, Tsimihodimos V, Elisaf MS. A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism 2012; 61:906–921.
MacRaild CA, Hatters DM, Howlett GJ, Gooley PR. NMR structure of human apolipoprotein C-II in the presence of sodium dodecyl sulfate. Biochemistry 2001; 40:5414–5421.
Zdunek J, Martinez GV, Schleucher J, et al. Global structure and dynamics of human apolipoprotein CII in complex with micelles: evidence for increased mobility of the helix involved in the activation of lipoprotein lipase. Biochemistry 2003; 42:1872–1889.
Kinnunen PK, Jackson RL, Smith LC, et al. Activation of lipoprotein lipase by native and synthetic fragments of human plasma apolipoprotein C-II. Proc Natl Acad Sci U S A 1977; 74:4848–4851.
Olivecrona G, Beisiegel U. Lipid binding of apolipoprotein CII is required for stimulation of lipoprotein lipase activity against apolipoprotein CII-deficient chylomicrons. Arterioscler Thromb Vasc Biol 1997; 17:1545–1549.
Goulbourne CN, Gin P, Tatar A, et al. The GPIHBP1-LPL complex is responsible for the margination of TG-rich lipoproteins in capillaries. Cell Metab 2014; 19:849–860.
Davies BS, Beigneux AP, Barnes RH 2nd, et al. GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell Metab 2010; 12:42–52.
Goldberg IJ, Eckel RH, Abumrad NA. Regulation of fatty acid uptake into tissues: lipoprotein lipase- and CD36-mediated pathways. J Lipid Res 2009; 50 Suppl:S86–S90.
Meyers NL, Larsson M, Olivecrona G, Small DM. A pressure-dependent model for the regulation of lipoprotein lipase by apolipoprotein C-II. J Biol Chem 2015; 290:18029–18044.
Huff MW, Fidge NH, Nestel PJ, et al. Metabolism of C-apolipoproteins: kinetics of C-II, C-III1 and C-III2, and VLDL-apolipoprotein B in normal and hyperlipoproteinemic subjects. J Lipid Res 1981; 22:1235–1246.
Shen Y, Lookene A, Nilsson S, Olivecrona G. Functional analyses of human apolipoprotein CII by site-directed mutagenesis: identification of residues important for activation of lipoprotein lipase. J Biol Chem 2002; 277:4334–4342.
Bengtsson G, Olivecrona T. Lipoprotein lipase: some effects of activator proteins. Eur J Biochem 1980; 106:549–555.
Lewis GF, Xiao C, Hegele RA. Hypertriglyceridemia in the genomic era: a new paradigm. Endocr Rev 2015; 36:131–147.
Berberich AJ, Hegele RA. The role of genetic testing in dyslipidaemia. Pathology 2019; 51:184–192.
Dron JS, Hegele RA. Polygenic influences on dyslipidemias. Curr Opin Lipidol 2018; 29:133–143.
Mantel-Teeuwisse AK, Kloosterman JM, Maitland-van der Zee AH, et al. Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Saf 2001; 24:443–456.
Brunzell JD, Deeb SS. Valle D, Antonarakis S, Ballabio A, et al. Familial lipoprotein lipase deficiency, Apo C-II deficiency, and hepatic lipase deficiency. The online metabolic and molecular bases of inherited disease. New York, NY: McGraw-Hill Education; 2019.
Gotoda T, Shirai K, Ohta T, et al. Research Committee for Primary Hyperlipidemia, Research on Measures against Intractable Diseases by the Ministry of Health, Labour and Welfare in JapanDiagnosis and management of type I and type V hyperlipoproteinemia. J Atheroscler Thromb 2012; 19:1–12.
Brahm AJ, Hegele RA. Chylomicronaemia--current diagnosis and future therapies. Nat Rev Endocrinol 2015; 11:352–362.
Bhatt DL, Steg PG, Miller M, et al. REDUCE-IT InvestigatorsCardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019; 380:11–22.
Larsen LE, Stoekenbroek RM, Kastelein JJP, Holleboom AG. Moving targets: recent advances in lipid-lowering therapies. Arterioscler Thromb Vasc Biol 2019; 39:349–359.
Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med 2015; 373:438–447.
Khetarpal SA, Zeng X, Millar JS, et al. A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower TG-rich lipoprotein levels. Nat Med 2017; 23:1086–1094.
Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med 2014; 371:2200–2206.
Graham MJ, Lee RG, Bell TA 3rd, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma TGs in rodents, nonhuman primates, and humans. Circ Res 2013; 112:1479–1490.
Gusarova V, Alexa CA, Wang Y, et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J Lipid Res 2015; 56:1308–1317.
Graham MJ, Lee RG, Brandt TA, et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med 2017; 377:222–232.
Gaudet D, Gipe DA, Pordy R, et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. N Engl J Med 2017; 377:296–297.
Ahmad Z, Banerjee P, Hamon S, et al. Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces TGs in hypertriglyceridemia. Circulation 2019; 140:470–486.
Jakob T, Nordmann AJ, Schandelmaier S, et al. Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev 2016; 11:CD009753.
Sethi AA, Stonik JA, Thomas F, et al. Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides. J Biol Chem 2008; 283:32273–32282.
Reimund M, Kovrov O, Olivecrona G, Lookene A. Lipoprotein lipase activity and interactions studied in human plasma by isothermal titration calorimetry. J Lipid Res 2017; 58:279–288.
Shachter NS, Hayek T, Leff T, et al. Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice. J Clin Invest 1994; 93:1683–1690.